An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes

摘要

Aim: This study aimed to assess the cost-effectiveness of starting insulin therapy with biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes inadequately controlled on oral glucose-lowering drugs in Saudi Arabia, India, Indonesia, and Algeria.